403
Sorry!!
Error! We're sorry, but the page you were looking for doesn't exist.
Novonesis Increases Outlook For Full Year 2024
(MENAFN- GlobeNewsWire - Nasdaq) Novonesis increases its full-year sales and profitability outlook based on the first half year performance coupled with strong momentum going into the first months of the second half.
The 2024 outlook is increased to:
. Pro forma organic sales growth of now 7-8% (previously“upper end of 5-7%”)
. Pro forma adjusted EBITDA margin of now 35.5-36.5% (previously“35-36%”)
Additional information is made available in the Company announcement: Interim Report H1 2024.
The 2024 outlook is increased to:
. Pro forma organic sales growth of now 7-8% (previously“upper end of 5-7%”)
. Pro forma adjusted EBITDA margin of now 35.5-36.5% (previously“35-36%”)
Additional information is made available in the Company announcement: Interim Report H1 2024.
Attachment
- 2024_26_Company_Announcement
Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept
any responsibility or liability for the accuracy, content, images,
videos, licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright
issues related to this article, kindly contact the provider above.
Most popular stories
More Story
Comments
No comment